What can I expect if I join the study?

If you qualify and choose to join the study and sign the informed consent form, you will be asked to attend up to 3 screening visits with the study doctor. At these visits, you will undergo tests and procedures to determine if you are a good match for continuing in the study.

- If eligible, you will be randomly assigned to 1 of 2 study treatment arms. This means you may receive the combination of the investigational medication and chemotherapy or chemotherapy alone.
- Chemotherapy is a standard of care treatment for NSCLC. If you receive chemotherapy alone, and your NSCLC gets worse, you may be able to receive the investigational medication in an extension of this study.
- Both you and the study staff will know which study treatment arm you have been assigned to.
- The investigational medication and/or chemotherapy will both be administered through intravenous infusions (needle inserted into a vein in the arm) on Day 1 of each study medication cycle. Each cycle will last 21 days.
- Qualified patients may receive investigational medication and some study-related care at no cost. The study will not pay for other medical care or current medication(s) needed to support your daily health care routine.

Can I change my mind?

Yes. You can quit the study at any time, for any reason. Even if you begin the study, you can change your mind at any point.

Janssen Research & Development, LLC
61186372NSC3001-ENG06
Version 1.0, 17Jul2020

What if your **Lung Cancer** path included a different approach?

For more information about this clinical research study, contact
(844) 414-1804

PAPILLON

janssen

Learn more about the PAPILLON research study that is evaluating an investigational medication for adults with advanced or metastatic non-small cell lung cancer (NSCLC) with a gene mutation called EGFR Exon 20 insertion.

A clinical study to evaluate the investigational combination of the study medication with chemotherapy in adults with advanced or metastatic non-small cell lung cancer (NSCLC) that has a gene mutation called EGFR Exon 20 insertion is now enrolling. Metastatic cancer is cancer that has spread to other parts of the body, and EGFR Exon 20 is a mutation that causes cells to continue to grow and divide.

Evaluating Investigational Medication through Clinical Research

What is a clinical research study?

A clinical trial, also called a clinical research study, is a carefully designed scientific evaluation of an investigational medication or treatment. Clinical trials are conducted by doctors and researchers.

Why is clinical research important?

Clinical research helps doctors and scientists determine if an investigational medication or therapies are safe and/or effective for use in humans to potentially treat a condition, disease or disorder. Clinical studies often require large number of volunteers to participate in a single study, and sometimes thousands are needed to obtain reliable information.

What is Informed Consent?

"Informed Consent" is a process of information exchange before an adult agrees to participate in research. Potential research participants will be asked to read and sign an informed consent document, but will also be given instructions, verbally and in writing, question/answer sessions and other reading materials to assure the potential study participants' understanding and willingness to voluntarily enroll in the research.

So before you agree to volunteer for the study, the study doctor or staff is required to explain all the details of the study, which will include the risks and benefits, and address your questions. After all of your questions have been answered, and if you wish to participate, then you will sign a document called the informed consent form to ensure:

- You agree to volunteer.
- You understand the study, including the study procedures, risks and potential side effects of the study medication.
- You understand that you can leave the study at any time, for any reason.

If you don't understand what is expected of you or the document, you should continue to ask questions and talk with the study doctor, your family or others that you trust, until you feel you understand.

Purpose of the PAPILLON study

The purpose of this clinical research study is to determine the effectiveness of a combination of an investigational medication with chemotherapy. This combination is being evaluated in people with advanced or metastatic NSCLC that has a gene mutation called EGFR Exon 20 insertion.

Am I eligible?

You may be able to participate in the PAPILLON study if you:

- Are 18 years of age or older
- Have been diagnosed with advanced or metastatic NSCLC that has a gene mutation called EGFR Exon 20 insertion
- Have not received any prior treatment for your advanced cancer

Additional eligibility criteria will be assessed by the study doctor or staff during the screening process prior to being enrolled in the study and receiving any investigational medication. Not all individuals may qualify to participate in the research.